APA

Niijima T., Akaza H., Koyanagi T., Togashi M., Kumamoto Y., Funyu T., Suzuki T., Orikasa S., Yoshikawa K. & Koiso K. (19930209). [Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors]. : Hinyokika kiyo. Acta urologica Japonica.

Chicago

Niijima T, Akaza H, Koyanagi T, Togashi M, Kumamoto Y, Funyu T, Suzuki T, Orikasa S, Yoshikawa K and Koiso K. 19930209. [Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors]. : Hinyokika kiyo. Acta urologica Japonica.

Harvard

Niijima T., Akaza H., Koyanagi T., Togashi M., Kumamoto Y., Funyu T., Suzuki T., Orikasa S., Yoshikawa K. and Koiso K. (19930209). [Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors]. : Hinyokika kiyo. Acta urologica Japonica.

MLA

Niijima T, Akaza H, Koyanagi T, Togashi M, Kumamoto Y, Funyu T, Suzuki T, Orikasa S, Yoshikawa K and Koiso K. [Combination therapy with natural type human tumor necrosis factor (MHR-24) and human lymphoblastoid interferon-alpha (MOR-22) against renal cell carcinoma--a multiclinic cooperative, early phase II study. Subcommittee on Urogenital Malignancy, Committee on MHR-24 against Tumors]. : Hinyokika kiyo. Acta urologica Japonica. 19930209.